Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer

Recruiting Phase 2 Interventional Study
Prostate Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Male
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
137 (estimated)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Prospective non-randomized phase 2 trial to study the efficacy of additional elective para-aortic RT (PART) in pN1 patients compared to those who were historically treated with adjuvant whole pelvic radiotherapy (WPRT) alone.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Signed informed consent and willingness to comply with the treatment and follow-up * Diagnosis of histopathologically confirmed prostate cancer * No former treatment for prostate cancer * Presence of pN1 disease after ePLND (criteria defined in the protocol) * Age \> 18 * Karn…
Contacts

Gert De Meerleer, Prof. Dr.

00 32 16 34 76 00

gert.demeerleer@uzleuven.be

CONTACT

Charlien Berghen, MD

00 32 16 34 52 17

charlien.berghen@uzleuven.be

CONTACT